Search

Your search keyword '"Rizzi, Rita"' showing total 482 results

Search Constraints

Start Over You searched for: Author "Rizzi, Rita" Remove constraint Author: "Rizzi, Rita"
482 results on '"Rizzi, Rita"'

Search Results

1. Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy

2. Relationship Between Bees Activity Level with Their Load of Lead, Cadmium and Selenium and Climatic Conditions of the Sites

5. Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma

6. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)

8. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

9. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

11. Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases

13. P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL

14. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis

15. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials

20. Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

21. How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

22. SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance

26. P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma

28. Genotypic and allelic frequency of a mutation in the NHEJ1 gene associated with collie eye anomaly in dogs in Italy

29. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

30. Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients

31. COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study

32. Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study

33. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

38. Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?

40. Amyloid in bone marrow smears of patients affected by multiple myeloma

42. Whole-Genome Sequence Analysis of Italian Honeybees (Apis mellifera)

43. Genotypic and allelic frequencies of MDR1 gene in dogs in Italy

48. What Is New in the Treatment of Smoldering Multiple Myeloma?

Catalog

Books, media, physical & digital resources